Procter & Gamble (PG) — Q4 FY2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup is mixed-to-cautious — consensus for Q4 FY2026 core EPS of ~$1.41–$1.43 is a low bar relative to recent beats, but the quarter carries an unusually heavy cost burden from Middle East-linked commodity, logistics, and reformulation headwinds (~$150M after-tax concentrated almost entirely in Q4), making organic sales the real swing factor heading into the print.

Heading into P&G's Q4 FY2026 print — the closing quarter of the first fiscal year under new CEO Shailesh Jejurikar — the bar is set low on EPS (~$1.41 consensus vs. $1.59 in Q3) but the revenue and organic sales line is where the real debate sits. Management guided Q4 organic sales growth to be somewhat lower than Q3's 3% due to Easter-related trade inventory pull-forward into Q3 (estimated ~1 point of volume), implying a Q4 organic print in the 1.5–2.5% range — consensus sits at ~1.6%, which is a low but achievable bar. On the cost side, the ~$150M after-tax Middle East headwind (commodity feedstocks, logistics, reformulation) was explicitly flagged as concentrated in Q4, creating meaningful EPS pressure that management has already guided toward the lower end of the full-year core EPS range of $6.83–$7.09; the stock has largely priced this in, trading at ~$152 and ~22x forward P/E — a modest discount to recent historical averages. Estimate revisions have drifted lower since the Q3 print (Q4 EPS consensus fell from ~$1.51 to ~$1.41), suggesting the street has already de-risked the quarter. The key wildcard is FY2027 guidance: management deferred FY27 guidance to this call, and the market will be laser-focused on how P&G frames the ~$1B after-tax oil/commodity headwind and whether productivity, sourcing, and innovation-linked pricing can credibly offset it — any constructive FY27 framing could be the catalyst for a relief rally despite a likely soft Q4 print.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a low bar on EPS (~$1.41 vs. $1.59 in Q3) given the flagged Q4 cost concentration, but organic sales growth (~1.6% consensus) is the bigger swing factor — any upside surprise there, combined with constructive FY27 commentary, could drive a positive stock reaction despite the EPS headwind.

Table 1 — Current Quarter Snapshot (Q4 FY2026)

Sources: Visible Alpha Consensus and Actuals Data; Q3 FY2026 Earnings Call (April 24, 2026); company guidance.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

Core EPS (Diluted Operating)

Organic Sales Growth (Consolidated %)

Pattern: P&G has beaten core EPS consensus in all 8 of the last 8 quarters, typically by 1–5%, reflecting a consistent management practice of conservative guidance. Organic sales has been more volatile, with 3 misses in 8 quarters — the Q4 FY2024 and Q3 FY2025 misses both coincided with periods of elevated competitive pressure and macro softness. The Q4 FY2026 organic bar (~1.6%) is the lowest in 8 quarters, reducing miss risk on that line.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has not been formally revised since the Q3 FY2026 earnings call (April 24, 2026), but management explicitly shifted tone toward the lower end of the full-year core EPS range due to the concentrated Q4 Middle East cost headwind — a meaningful de facto downward revision in tone even without a formal range change. FY2027 guidance is the critical new variable at this print.

Source: P&G Q3 FY2026 Earnings Call Transcript (April 24, 2026); Visible Alpha Consensus Data.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have drifted meaningfully lower since the Q3 FY2026 print — Q4 core EPS consensus fell ~6.6% from ~$1.51 to ~$1.41, tracking management's explicit lower-end guidance tone. Organic sales estimates for Q4 also declined from ~2.5% to ~1.6%, consistent with the Easter pull-forward warning. FY2027 estimates are essentially unchanged, suggesting the street is waiting for management's first formal FY27 guidance at this call before making significant revisions.

The ~6.6% decline in Q4 EPS consensus since the Q3 print reflects the market absorbing management's explicit lower-end guidance tone and the ~$150M after-tax Q4 cost headwind. The flat FY2027 consensus is the key tell — the street is holding estimates in place pending the first formal FY27 guidance at this call, creating asymmetric upside if management frames the ~$1B oil headwind as manageable through productivity and pricing.

Source: Visible Alpha Consensus and Actuals Data; P&G Q3 FY2026 Earnings Call (April 24, 2026).

5. Stock Performance

Key Takeaway: PG has outperformed both XLP and the S&P 500 since the Q3 FY2026 earnings print (April 24, 2026), rising ~+6.4% (indexed) vs. XLP +3.9% and SPY +7.8% — the move appears driven by multiple stabilization and defensive rotation rather than estimate upgrades, as EPS revisions have actually moved lower. The stock enters Q4 earnings at ~$152, near its 52-week high range, suggesting limited margin of safety if the FY2027 guidance disappoints.

PG vs. XLP (Consumer Staples ETF) vs. S&P 500 — Indexed to 100 at Q3 FY2026 Earnings Date (April 24, 2026). Sector ETF: XLP (Consumer Staples Select Sector SPDR), appropriate for P&G's household & personal care sub-sector. Material events marked: Q3 FY26 Earnings (Apr 24) and JPMorgan PT cut (Jul 16). Note: Price data is approximate based on publicly available sources.

PG's ~6.4% gain since the Q3 print has been driven primarily by multiple stabilization and defensive rotation into consumer staples as macro uncertainty elevated — not by upward estimate revisions, which have actually moved lower. The stock's 52-week range of $137.62–$167.25 and current ~22x forward P/E (below the ~38x market average) reflects a balanced sentiment: no longer stretched, but not cheap enough to provide a meaningful cushion if FY2027 guidance disappoints. JPMorgan's July 16 PT cut from $164 to $162 (maintaining Overweight) and Wells Fargo's post-Q3 upgrade to $164 (Overweight) bracket the current consensus PT of ~$161.74, implying ~7% upside from current levels. The stock's low beta (0.39) and 2.86% dividend yield provide downside support.

6. Peer Commentaries — Read-Throughs from Last 60 Days

Key Takeaway: Peer commentary from Unilever (H1 2026, reported July 28), Colgate-Palmolive (Q1 2026, reported May 1), and Kimberly-Clark (Q1 2026, reported April 28) collectively signals that volume-led growth is achievable in the current environment but commodity/logistics inflation from the Middle East conflict is a shared industry headwind — the key read-through for PG is that peers are managing through it with productivity and selective pricing, validating P&G's stated approach, while Unilever's best quarterly volume performance since 2010 (+5.5% in Q2) sets a high bar for what innovation-led execution can deliver.

Note: Only commentary from peers' most recent earnings calls (reporting on their current quarter, i.e., Q1 2026 or H1 2026) is included below. Prior-quarter results commentary has been excluded.

Unilever (ULVR LN) — H1 2026 Results (Reported July 28, 2026)

Relevance to PG: Unilever is P&G's closest global peer across HPC (Home & Personal Care) and competes directly in fabric care, personal care, and beauty. Unilever's H1 2026 results are the most timely and directly comparable read-through for PG's Q4 FY2026 (calendar Q2 2026).

• Volume surge: Unilever reported Q2 2026 underlying sales growth of +5.8% with volume up +5.5% — its best quarterly volume performance since 2010. Power brands (78% of turnover) grew +6.9% with +6.8% volume. This is a strong positive read-through for category health and consumer willingness to trade up on innovation.
• North America outperformance: Unilever's North America grew +2.6% in Q2 with +4.4% volume, led by deodorants, skin cleansing, and prestige beauty. Unilever regained market leadership in US deodorants after two years — a competitive signal for P&G's personal care portfolio. Destocking in the US was described as "not material" at the company level, a positive read-through for PG's North America volume trajectory.
• China mid-single digit growth: Unilever's China grew mid-single digit in Q2, led by beauty and wellbeing, with all business groups contributing. The market is "getting slowly better" with good acceleration in food service. This is consistent with P&G's Q3 commentary of China returning to slight growth in the low-to-mid single digit range.
• Commodity inflation headwind: Unilever flagged ~€850M full-year commodity inflation (range €800–900M), with ~€550M in H2 2026, driven by crude, vegetable oils, packaging, and energy — explicitly citing the Middle East conflict as the source of inflation headwinds. Supply security was described as an "absolute priority." This validates P&G's ~$150M Q4 cost headwind framing and suggests the industry-wide cost pressure is real and concentrated in H2.
• Pricing to build in H2: Unilever guided for pricing to lead growth in H2 2026 as higher commodity costs are reflected in the market, with full-year USG expected within the 4–6% multi-year range. This supports P&G's thesis that innovation-linked pricing is the right lever, not broad-based price increases.
• FY2026 guidance upgraded: Unilever upgraded its full-year outlook to within its 4–6% multi-year USG range with ~3% volume for the full year — a constructive signal for category health heading into P&G's Q4 print.

Colgate-Palmolive (CL) — Q1 2026 Results (Reported May 1, 2026)

Relevance to PG: Colgate competes directly with P&G in oral care, personal care, and home care. CL's Q1 2026 results (calendar Q1 2026) are a read-through for the consumer and competitive environment P&G faced in its Q4 FY2026 (calendar Q2 2026).

• Organic growth acceleration: Colgate reported Q1 2026 organic sales growth of +2.9% (volume +1.1%, pricing +1.8%) — its fastest clip in five quarters, with growth led by emerging markets. This is a positive read-through for category health, though North America lagged.
• North America weakness: North America continued to lag in volume/mix in Q1, with margins significantly pressured by tariffs (minimal in prior year) and higher raw material costs. Colgate is executing a strategy reset for North America involving brand interventions, accelerated innovation, and enhanced RGM. Sequential improvement was expected in Q2 — a read-through that the North America competitive environment may be stabilizing for P&G as well.
• Commodity cost escalation: Since the Q4 2025 call, Colgate identified an additional ~$300M of raw materials and logistics impact for the year (2/3 raw materials, 1/3 logistics), with oil assumed at ~$110/bbl for the remainder of the year. Spending on oil byproducts (resins, petrochemicals, fats, oils) expected up more than 20% year-on-year; logistics costs up nearly 10%. This is a strong validation of P&G's commodity headwind framing.
• Pricing philosophy aligned with PG: Colgate CEO Noel Wallace stated pricing must be "coupled with strong innovation" and that the company will "take pricing where we see the opportunities" — directly echoing P&G's innovation-linked pricing philosophy. Both companies are rejecting broad-based price increases in favor of consumer-choice-based innovation pricing.
• Gross margin guidance reduced: Colgate reduced its gross margin expectations for the year while maintaining EPS guidance in the low-to-mid single digit range, absorbing the $300M cost headwind through productivity. This is consistent with P&G's approach of protecting EPS through productivity while absorbing cost pressure.
• China: Colgate's China business delivered mid-single-digit growth in a flat-to-declining market, with interventions in the Hawley & Hazel business paying dividends. Consistent with P&G's China narrative of selective outperformance in a challenging macro environment.

Kimberly-Clark (KMB) — Q1 2026 Results (Reported April 28, 2026)

Relevance to PG: Kimberly-Clark competes directly with P&G in baby care (Huggies vs. Pampers), feminine care, and family care. KMB's Q1 2026 results are the most direct competitive read-through for P&G's Baby, Feminine & Family Care segment.

• Volume-led growth: KMB reported Q1 2026 volume plus mix growth of +3.0%, its ninth or tenth consecutive quarter of solid volume/mix growth, driven by innovation rather than promotion. North America categories rebounded strongly in Q1 with category growth of ~3.3%. This is a positive read-through for P&G's North America volume trajectory.
• Baby Care competitive dynamics: KMB is building market share in Baby Care, Women's Health, and Active Aging. The company brought its best product technology from China into the value tier in North America — a direct competitive signal for P&G's Pampers business, which management has described as facing a "tale of two cities" with U.S. challenges from Chinese import brands.
• Middle East commodity headwind: KMB flagged a ~$50M bottom-line Q2 impact from Middle East war-related inflation and the LA DC fire, with potential gross incremental input costs of $150–$170M in H2 2026 if oil stays at ~$100/bbl — not yet built into guidance. This is a direct validation of P&G's ~$150M Q4 cost headwind and suggests the industry-wide pressure is real.
• Consumer behavior: KMB observed no large-scale shifts in consumer buying behavior, with consumers "getting more choiceful" but branded value propositions winning in mid-price tiers. Private label penetration in personal care continues to fall. This is a constructive read-through for P&G's premium brand positioning.
• Margin resilience: KMB maintained full-year guidance for gross and operating margin expansion of ~70–80bp despite the emerging commodity pressures, citing a strong track record of recovering input cost inflation. The company is ~80% covered in its cost basket through hedging and contracts — a more favorable position than P&G's more exposed supply chain.

Church & Dwight (CHD) — Q1 2026 Results (Reported May 1, 2026)

Relevance to PG: Church & Dwight competes with P&G in laundry (ARM & HAMMER vs. Tide), oral care (THERABREATH vs. Oral-B), and personal care. CHD's Q1 2026 results provide a read-through on category health and competitive dynamics in P&G's core U.S. household categories.

• Strongest volume print among peers: CHD reported Q1 2026 organic sales growth of +5.0% with volume +5.3% — the highest volume growth among HPC peers in the quarter (vs. CL +1.1%, PG +2.0%, KMB +3.0%). Domestic organic grew +5.4%, primarily all volume. This suggests category health in P&G's core U.S. household categories is robust.
• Laundry category dynamics: ARM & HAMMER laundry achieved record shares with consumption growing +4.1% vs. category growth of +2.7%. The value segment of laundry continues to grow — a competitive signal for P&G's Tide franchise, which has been executing innovation-led interventions (Tide liquid formula upgrade driving mid-teens growth in Q3 FY2026).
• Consumer backdrop: CHD management characterized the consumer as "pressed" with "no appetite" for price increases, with the company explicitly declining to price through its $25–30M incremental inflation headwind. Category growth for CHD's major categories was ~3% in Q1, with March at ~3.5% — better than the 2% expected at the start of the year. This is a constructive read-through for P&G's U.S. category growth assumptions.
• Middle East commodity headwind: CHD estimated $25–30M of incremental full-year inflation pressure from oil-based derivatives (diesel, resin, surfactants) at an assumed oil price of $95–$100/bbl. The company plans to offset through productivity rather than pricing — consistent with the industry-wide approach and validating P&G's cost headwind framing.

Sources: Unilever H1 2026 Earnings Call Transcript (July 28, 2026); Colgate-Palmolive Q1 2026 Earnings Call Transcript (May 1, 2026); Kimberly-Clark Q1 2026 Earnings Call Transcript (April 28, 2026); Church & Dwight Q1 2026 Earnings Call Transcript (May 1, 2026).

7. Material News & Developments

Key Takeaway: The most important development since the Q3 FY2026 print is the Middle East conflict-driven commodity cost escalation — flagged as a ~$150M after-tax Q4 headwind with a potential ~$1B after-tax FY2027 impact if oil stays at ~$100/bbl — which has reset near-term EPS expectations and makes FY2027 guidance the single most important variable at tomorrow's print.

• April 24, 2026 — Q3 FY2026 Earnings: P&G reported Q3 core EPS of $1.59 (beat vs. $1.56 consensus) and organic sales of +3% (beat vs. +1.9% consensus), but guided Q4 organic sales lower due to Easter pull-forward and flagged ~$150M after-tax Middle East cost headwind concentrated in Q4. Full-year EPS guided toward the lower end of $6.83–$7.09. Stock rose in premarket but sold off on the day amid analyst PT cuts. Implication: Sets a low bar for Q4 EPS but creates high stakes for FY2027 guidance.
• April 24, 2026 — Middle East Conflict Cost Quantification: Management quantified the annualized FY2027 cost impact of Brent crude at ~$100/bbl as ~$1.3B before tax / ~$1B after tax vs. pre-conflict oil in the mid-$60s, encompassing commodity feedstocks, sourcing lane changes, reformulation upcharges, and finished product logistics. Supply chain demonstrated resilience with no stockouts on key materials. Implication: The magnitude of this headwind is the central debate for FY2027 EPS; management's mitigation roadmap is the key watch item.
• April 24, 2026 — FY2027 Guidance Deferred: Management explicitly deferred FY2027 guidance to the Q4 call (July 29), stating it is "a work in progress" dependent on productivity, sourcing choices, and innovation-linked pricing. An Investor Day in November 2026 was confirmed to showcase new leadership and strategic pillars. Implication: Tomorrow's call is the first opportunity for the market to hear FY2027 framing — the single biggest catalyst for the stock.
• April 27, 2026 — Analyst Rating/PT Changes Post-Q3: Wells Fargo raised PT from $158 to $164 (Overweight); UBS raised PT from $166 to $172 (Buy); Rothschild & Co Redburn cut PT from $157 to $155 (Neutral); TD Cowen raised PT from $142 to $150 (Hold). Consensus rating: Moderate Buy with average PT of ~$161.74. Implication: Constructive analyst sentiment with 12 Buy / 9 Hold ratings; no Sells.
• May 1, 2026 — Peer Earnings (CL, CHD): Colgate and Church & Dwight both reported Q1 2026 results, validating the industry-wide commodity cost headwind from the Middle East conflict and confirming that volume-led growth is achievable through innovation. Both companies maintained full-year guidance. Implication: Positive read-through for category health; validates P&G's cost headwind framing.
• July 16, 2026 — JPMorgan PT Cut: JPMorgan Chase lowered its price target on PG from $164 to $162 while maintaining an Overweight rating, citing the commodity cost headwind and lower-end EPS guidance tone. The new target implies ~7.5% upside from the prior close. Implication: Modest valuation reset; constructive overall tone maintained.
• July 28, 2026 — Unilever H1 2026 Results: Unilever reported its best quarterly volume performance since 2010 (+5.5% in Q2) and upgraded its full-year USG outlook to within the 4–6% multi-year range, while flagging ~€850M full-year commodity inflation from the Middle East conflict. Implication: Strong positive read-through for category health and volume-led growth potential; validates commodity headwind.
• Ongoing — Restructuring Program: P&G is cutting up to 7,000 non-manufacturing roles by end of FY2027, with ~$1.0–$1.6B in non-core restructuring charges over two years. After year one, slightly more than half of targeted role reductions have been executed. Implication: Restructuring savings provide a productivity offset to commodity headwinds; progress update expected at Q4 call.
• Ongoing — U.S. Baby Care Competition: Chinese import brands (Rascal & Friends, Zuru-affiliated) continue to gain retail footholds in U.S. diapers. Management has adapted near-term value competitiveness, returning diapers to share growth in recent measured periods. Implication: Watch for any update on Baby Care U.S. share trajectory and innovation pipeline timing.

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells by executives or directors since the Q3 FY2026 earnings print. The only Form 4 activity in the period was routine director compensation grants (transaction code A) on June 9, 2026 — six directors received stock awards as part of standard board compensation. Nothing notable to flag; the absence of open-market buying by insiders ahead of a potentially pivotal FY2027 guidance call is worth noting but is not unusual for a large-cap staples company.

All six transactions on June 9, 2026 are routine director stock award grants (SEC Form 4, transaction code A — Acquisition via award/grant), not open-market purchases. There are no open-market buys (code P) or discretionary sells (code S) by any executive officer or director in the period since the Q3 FY2026 earnings print (April 24, 2026). No 10b5-1 plan initiations or Form 144 filings were identified in the period.

Source: SEC Form 4 Filings Database (Insider Transaction Data).